$PLUR
Pluri Inc. Stock $plur

$plur Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-Q Financial Statement

#000121390024012549 Filed on February 12, 2024

Income Statement

Concept	2024 Q1	2023 Q4
Revenue	$71.00K	$105.0K
YoY Change	-18.39%	5150.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.511M	$2.354M
YoY Change	-16.85%	-18.72%
% of Gross Profit
Research & Development	$3.094M	$2.964M
YoY Change	-28.59%	-35.21%
% of Gross Profit
Depreciation & Amortization	$61.00K	$61.00K
YoY Change	-30.68%	-37.11%
% of Gross Profit
Operating Expenses	$3.094M	$2.964M
YoY Change	-28.59%	-35.21%
Operating Profit	-$5.534M	-$5.213M
YoY Change	-22.06%	-21.95%
Interest Expense	$218.0K	$216.0K
YoY Change	-200.46%	-201.89%
% of Operating Profit
Other Income/Expense, Net	$144.0K	$219.0K
YoY Change	-132.65%	-116.07%
Pretax Income	-$5.390M	-$4.994M
YoY Change	-30.52%	-39.5%
Income Tax
% Of Pretax Income
Net Earnings	-$5.293M	-$4.905M
YoY Change	-30.57%	-39.57%
Net Earnings / Revenue	-7454.93%	-4671.43%
Basic Earnings Per Share	-$1.01	-$0.12
Diluted Earnings Per Share	-$1.01	-$0.12
COMMON SHARES
Basic Shares Outstanding	41.48M shares	41.48M shares
Diluted Shares Outstanding	5.221M shares	41.53M shares

Balance Sheet

Concept	2024 Q1	2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$26.01M	$30.62M
YoY Change	-41.12%	-35.19%
Cash & Equivalents	$7.081M	$5.468M
Short-Term Investments	$18.93M	$25.15M
Other Short-Term Assets	$1.360M	$1.632M
YoY Change	-46.01%	-43.61%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$27.37M	$32.25M
YoY Change	-41.38%	-35.68%
LONG-TERM ASSETS
Property, Plant & Equipment	$769.0K	$788.0K
YoY Change	12.92%	17.09%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$7.000K	$79.00K
YoY Change	250.0%	-18.56%
Total Long-Term Assets	$9.023M	$9.312M
YoY Change	-5.56%	-4.85%
TOTAL ASSETS
Total Short-Term Assets	$27.37M	$32.25M
Total Long-Term Assets	$9.023M	$9.312M
Total Assets	$36.39M	$41.56M
YoY Change	-35.3%	-30.64%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.030M	$1.104M
YoY Change	-29.11%	-12.17%
Accrued Expenses	$958.0K	$1.012M
YoY Change	-28.24%	-32.85%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$4.526M	$4.530M
YoY Change	-15.83%	-14.27%
LONG-TERM LIABILITIES
Long-Term Debt	$24.07M	$24.40M
YoY Change	3.08%	7.61%
Other Long-Term Liabilities	$5.954M	$6.016M
YoY Change	-10.29%	-14.08%
Total Long-Term Liabilities	$30.02M	$30.42M
YoY Change	0.12%	2.49%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.526M	$4.530M
Total Long-Term Liabilities	$30.02M	$30.42M
Total Liabilities	$34.55M	$34.95M
YoY Change	-2.3%	-0.04%
SHAREHOLDERS EQUITY
Retained Earnings	-$414.7M	-$409.5M
YoY Change	5.5%	6.21%
Common Stock	$0.00	$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$356.0K	$4.399M
YoY Change
Total Liabilities & Shareholders Equity	$36.39M	$41.56M
YoY Change	-35.3%	-30.64%

Cashflow Statement

Concept	2024 Q1	2023 Q4
OPERATING ACTIVITIES
Net Income	-$5.293M	-$4.905M
YoY Change	-30.57%	-39.57%
Depreciation, Depletion And Amortization	$61.00K	$61.00K
YoY Change	-30.68%	-37.11%
Cash From Operating Activities	-$4.202M	-$3.646M
YoY Change	-30.79%	-41.94%
INVESTING ACTIVITIES
Capital Expenditures	$89.00K	$124.0K
YoY Change	270.83%	82.35%
Acquisitions
YoY Change
Other Investing Activities	$5.757M	$4.035M
YoY Change	-445.97%	447.49%
Cash From Investing Activities	$5.668M	$3.921M
YoY Change	-435.78%	486.1%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	0.000
YoY Change	-100.0%	-100.0%
NET CHANGE
Cash From Operating Activities	-4.202M	-3.646M
Cash From Investing Activities	5.668M	3.921M
Cash From Financing Activities	0.000	0.000
Net Change In Cash	1.466M	275.0K
YoY Change	-127.06%	235.37%
FREE CASH FLOW
Cash From Operating Activities	-$4.202M	-$3.646M
Capital Expenditures	$89.00K	$124.0K
Free Cash Flow	-$4.291M	-$3.770M
YoY Change	-29.6%	-40.61%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity Address Address Line1 EntityAddressAddressLine1	MATAM Advanced Technology Park
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Building No. 5
	dei	Entity Address City Or Town EntityAddressCityOrTown	Haifa
	dei	Entity Address Country EntityAddressCountry	IL
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	41480172	shares
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5468000	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5360000	usd
CY2023Q4	plur	Shortterm Bank Deposits ShorttermBankDeposits	25152000	usd
CY2023Q2	plur	Shortterm Bank Deposits ShorttermBankDeposits	34811000	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	373000	usd
CY2023Q2	us-gaap	Restricted Cash RestrictedCash	269000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1259000	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	969000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	32252000	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	41409000	usd
CY2022Q4	plur	Research And Development Expenses ResearchAndDevelopmentExpenses	4575000	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	645000	usd
CY2023Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	627000	usd
CY2023Q4	us-gaap	Defined Benefit Plan Assets For Plan Benefits Noncurrent DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent	460000	usd
CY2023Q2	us-gaap	Defined Benefit Plan Assets For Plan Benefits Noncurrent DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent	439000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	788000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	688000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7340000	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7633000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	79000	usd
CY2023Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1000	usd
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	9312000	usd
CY2023Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	9388000	usd
CY2023Q4	us-gaap	Assets Assets	41564000	usd
CY2023Q2	us-gaap	Assets Assets	50797000	usd
CY2023Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	1104000	usd
CY2023Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	1812000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1012000	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1209000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	654000	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	627000	usd
CY2023Q4	plur	Accrued Vacations Current AccruedVacationsCurrent	779000	usd
CY2023Q2	plur	Accrued Vacations Current AccruedVacationsCurrent	873000	usd
CY2023Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	981000	usd
CY2023Q2	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	1100000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4530000	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	5621000	usd
CY2023Q4	us-gaap	Postemployment Benefits Liability Noncurrent PostemploymentBenefitsLiabilityNoncurrent	613000	usd
CY2023Q2	us-gaap	Postemployment Benefits Liability Noncurrent PostemploymentBenefitsLiabilityNoncurrent	598000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5403000	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5748000	usd
CY2023Q4	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	24401000	usd
CY2023Q2	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	23530000	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	30417000	usd
CY2023Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	29876000	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	41680023	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41680023	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	41245495	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41245495	shares
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	413849000	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	412939000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-409450000	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-399584000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	4399000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	13355000	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	2218000	usd
CY2023Q2	us-gaap	Minority Interest MinorityInterest	1945000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	6617000	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	15300000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	41564000	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	50797000	usd
	us-gaap	Revenues Revenues	159000	usd
	us-gaap	Revenues Revenues	89000	usd
CY2023Q4	us-gaap	Revenues Revenues	105000	usd
CY2022Q4	us-gaap	Revenues Revenues	2000	usd
	plur	Research And Development Expenses ResearchAndDevelopmentExpenses	6704000	usd
	plur	Research And Development Expenses ResearchAndDevelopmentExpenses	9079000	usd
CY2023Q4	plur	Research And Development Expenses ResearchAndDevelopmentExpenses	3338000	usd
	plur	Government And Third Party Grants Received GovernmentAndThirdPartyGrantsReceived	747000	usd
	plur	Government And Third Party Grants Received GovernmentAndThirdPartyGrantsReceived	1023000	usd
CY2023Q4	plur	Government And Third Party Grants Received GovernmentAndThirdPartyGrantsReceived	374000	usd
CY2022Q4	plur	Government And Third Party Grants Received GovernmentAndThirdPartyGrantsReceived	790000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5957000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8056000	usd
CY2023Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2964000	usd
CY2022Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3785000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4792000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5635000	usd
CY2023Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2354000	usd
CY2022Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2896000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-10590000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-13602000	usd
CY2023Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-5213000	usd
CY2022Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-6679000	usd
	us-gaap	Interest Expense InterestExpense	430000	usd
	us-gaap	Interest Expense InterestExpense	406000	usd
CY2023Q4	us-gaap	Interest Expense InterestExpense	216000	usd
CY2022Q4	us-gaap	Interest Expense InterestExpense	212000	usd
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	928000	usd
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-515000	usd
CY2023Q4	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	435000	usd
CY2022Q4	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-1363000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	498000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-921000	usd
CY2023Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	219000	usd
CY2022Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1575000	usd
	us-gaap	Profit Loss ProfitLoss	-10092000	usd
	us-gaap	Profit Loss ProfitLoss	-14523000	usd
CY2023Q4	us-gaap	Profit Loss ProfitLoss	-4994000	usd
CY2022Q4	us-gaap	Profit Loss ProfitLoss	-8254000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-226000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-285000	usd
CY2023Q4	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-89000	usd
CY2022Q4	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-137000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9866000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-14238000	usd
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	-4905000	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-8117000	usd
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.24
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.44
CY2023Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.12
CY2022Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.24
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	41428439	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32878434	shares
CY2023Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	41526817	shares
CY2022Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33194622	shares
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	32186000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	1897000	usd
	plur	Net Of Issuance Costs NetOfIssuanceCosts	361000	usd
	plur	Issuance Of Common Stock And Warrants IssuanceOfCommonStockAndWarrants	5406000	usd
	us-gaap	Profit Loss ProfitLoss	-14523000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	24966000	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	26901000	usd
CY2022Q4	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	913000	usd
CY2022Q4	plur	Net Of Issuance Costs NetOfIssuanceCosts	361000	usd
CY2022Q4	plur	Issuance Of Common Stock And Warrants IssuanceOfCommonStockAndWarrants	5406000	usd
CY2022Q4	us-gaap	Profit Loss ProfitLoss	-8254000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	24966000	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	15300000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	1409000	usd
	us-gaap	Profit Loss ProfitLoss	-10092000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	6617000	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	11038000	usd
CY2023Q4	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	573000	usd
CY2023Q4	us-gaap	Profit Loss ProfitLoss	-4994000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	6617000	usd
	us-gaap	Profit Loss ProfitLoss	-10092000	usd
	us-gaap	Profit Loss ProfitLoss	-14523000	usd
	us-gaap	Depreciation Depreciation	131000	usd
	us-gaap	Depreciation Depreciation	197000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1409000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1897000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	299000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	500000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-713000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-517000	usd
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-410000	usd
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-1290000	usd
	plur	Increasedecrease In Operating Lease Rightofuse Asset And Liability Net IncreasedecreaseInOperatingLeaseRightofuseAssetAndLiabilityNet	25000	usd
	plur	Increasedecrease In Operating Lease Rightofuse Asset And Liability Net IncreasedecreaseInOperatingLeaseRightofuseAssetAndLiabilityNet	-113000	usd
	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	-3000	usd
	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	388000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-373000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	111000	usd
	us-gaap	Increase Decrease In Long Term Receivables Current IncreaseDecreaseInLongTermReceivablesCurrent	2000	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	871000	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	997000	usd
	us-gaap	Increase Decrease In Pension And Postretirement Obligations IncreaseDecreaseInPensionAndPostretirementObligations	-6000	usd
	us-gaap	Increase Decrease In Pension And Postretirement Obligations IncreaseDecreaseInPensionAndPostretirementObligations	14000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9506000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13889000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	224000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	141000	usd
	us-gaap	Payments For Proceeds From Short Term Investments PaymentsForProceedsFromShortTermInvestments	-10012000	usd
	us-gaap	Payments For Proceeds From Short Term Investments PaymentsForProceedsFromShortTermInvestments	-7203000	usd
	plur	Proceeds From Investment In Long Term Deposits ProceedsFromInvestmentInLongTermDeposits	-67000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	9721000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	7062000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5693000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5693000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	15000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-111000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	230000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1245000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6256000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11413000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6486000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10168000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5468000	usd
CY2022Q4	us-gaap	Warrant Exercise Price Increase WarrantExercisePriceIncrease	1.12
CY2022Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P3Y
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8818000	usd
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	373000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	753000	usd
CY2023Q4	us-gaap	Restricted Cash Equivalents RestrictedCashEquivalents	645000	usd
CY2022Q4	us-gaap	Restricted Cash Equivalents RestrictedCashEquivalents	597000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6486000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	10168000	usd
	plur	Purchase Of Propertys And Equipment On Credit PurchaseOfPropertysAndEquipmentOnCredit	80000	usd
	plur	Purchase Of Propertys And Equipment On Credit PurchaseOfPropertysAndEquipmentOnCredit	15000	usd
	plur	Accrued Expenses Related To Issuance Of Common Shares And Warrants AccruedExpensesRelatedToIssuanceOfCommonSharesAndWarrants	287000	usd
	plur	Supplemental Noncash Information Related To Lease Liabilities Arising From Obtaining Rightofuse As SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingRightofuseAs	78000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>c.</i></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Use of estimates</i></b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates, judgments and assumptions that are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p>
CY2020Q2	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	50000000	eur
CY2021Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	20000000	eur
CY2021Q2	plur	Due Date DueDate	2026-06-01
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	1018000	usd
	plur	Percentage Of Qualified Expenditures PercentageOfQualifiedExpenditures	0.50	pure
	plur	Royalty Rate Sales RoyaltyRateSales	0.03	pure
	plur	Royalty Rate Payable On Grants Received RoyaltyRatePayableOnGrantsReceived	1	pure
CY2023Q4	plur	Contingent Liability In Respect To Royalties ContingentLiabilityInRespectToRoyalties	27669000	usd
CY2023Q4	us-gaap	Investment Owned Balance Principal Amount InvestmentOwnedBalancePrincipalAmount	22121000	usd
CY2022Q4	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	8155900	shares
CY2022Q4	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	8155900	shares
CY2022Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	1.03
CY2022Q4	us-gaap	Common Unit Issued CommonUnitIssued	5579883	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	5579833	shares
CY2022Q4	us-gaap	Warrant Exercise Price Increase WarrantExercisePriceIncrease	1.03
CY2022Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P3Y
CY2022Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	1.05
CY2022Q4	us-gaap	Common Unit Issued CommonUnitIssued	2068517	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	2068517	shares
CY2022Q4	us-gaap	Warrant Exercise Price Increase WarrantExercisePriceIncrease	1.05
CY2022Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P3Y
CY2022Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	1.06
CY2022Q4	us-gaap	Common Unit Issued CommonUnitIssued	237500	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	237500	shares
CY2022Q4	us-gaap	Warrant Exercise Price Increase WarrantExercisePriceIncrease	1.06
CY2022Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P3Y
CY2022Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	1.09
CY2022Q4	us-gaap	Common Unit Issued CommonUnitIssued	135000	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	135000	shares
CY2022Q4	us-gaap	Warrant Exercise Price Increase WarrantExercisePriceIncrease	1.09
CY2022Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P3Y
CY2022Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	1.12
CY2022Q4	us-gaap	Common Unit Issued CommonUnitIssued	135000	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	135000	shares
CY2023Q1	us-gaap	Common Unit Issued CommonUnitIssued	7015900	shares
	plur	Aggregate Gross Proceeds AggregateGrossProceeds	7300000	usd
CY2023Q4	us-gaap	Common Unit Issued CommonUnitIssued	8155900	shares
CY2023Q4	plur	Aggregate Amount Received AggregateAmountReceived	2500000	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	1657592	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	1935014	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	334821	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	1007165	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	39138	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	354027	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	212287	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	296400	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	2018410	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	285379	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1994118	shares
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	74000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	93000	usd
CY2023Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	36000	usd
CY2022Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	55000	usd
	plur	Modification Of Warrants To Noncontrolling Interests ModificationOfWarrantsToNoncontrollingInterests		usd
	plur	Expiration Of Warrants In Ever After ExpirationOfWarrantsInEverAfter		usd
CY2022Q4	plur	Expiration Of Warrants In Ever After ExpirationOfWarrantsInEverAfter		usd
	us-gaap	Increase Decrease In Long Term Receivables Current IncreaseDecreaseInLongTermReceivablesCurrent		usd
	plur	Proceeds From Investment In Long Term Deposits ProceedsFromInvestmentInLongTermDeposits		usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
	plur	Accrued Expenses Related To Issuance Of Common Shares And Warrants AccruedExpensesRelatedToIssuanceOfCommonSharesAndWarrants		usd
	plur	Supplemental Noncash Information Related To Lease Liabilities Arising From Obtaining Rightofuse As SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingRightofuseAs		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod		shares
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Entity Central Index Key EntityCentralIndexKey	0001158780

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001213900-24-012549-index-headers.html	Edgar Link	pending
0001213900-24-012549-index.html	Edgar Link	pending
0001213900-24-012549.txt	Edgar Link	pending
0001213900-24-012549-xbrl.zip	Edgar Link	pending
f10q1223ex10-1_pluriinc.htm	Edgar Link	pending
f10q1223ex10-2_pluriinc.htm	Edgar Link	pending
f10q1223ex10-3_pluriinc.htm	Edgar Link	pending
f10q1223ex10-4_pluriinc.htm	Edgar Link	pending
f10q1223ex10-5_pluriinc.htm	Edgar Link	pending
f10q1223ex10-6_pluriinc.htm	Edgar Link	pending
f10q1223ex10-7_pluriinc.htm	Edgar Link	pending
f10q1223ex31-1_pluriinc.htm	Edgar Link	pending
f10q1223ex31-2_pluriinc.htm	Edgar Link	pending
f10q1223ex32-1_pluriinc.htm	Edgar Link	pending
f10q1223ex32-2_pluriinc.htm	Edgar Link	pending
f10q1223_pluriinc.htm	Edgar Link	pending
f10q1223_pluriinc_htm.xml	Edgar Link	completed
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
plur-20231231.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
plur-20231231_def.xml	Edgar Link	unprocessable
plur-20231231_lab.xml	Edgar Link	unprocessable
plur-20231231_pre.xml	Edgar Link	unprocessable
plur-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PLUR
Pluri Inc. Stock $plur

2024 Q1 Form 10-Q Financial Statement

#000121390024012549 Filed on February 12, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PLUR Pluri Inc. Stock $plur

2024 Q1 Form 10-Q Financial Statement

#000121390024012549 Filed on February 12, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PLUR
Pluri Inc. Stock $plur